Aralez Pharmaceuticals Inc. (ARLZ) Director Buys $143,100.00 in Stock
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Director Seth Rudnick purchased 30,000 shares of the stock in a transaction dated Friday, November 11th. The shares were acquired at an average cost of $4.77 per share, with a total value of $143,100.00. Following the acquisition, the director now directly owns 94,391 shares in the company, valued at approximately $450,245.07. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) opened at 5.17 on Friday. The company’s market cap is $337.30 million. The firm has a 50 day moving average price of $4.68 and a 200-day moving average price of $4.32. Aralez Pharmaceuticals Inc. has a 52-week low of $3.10 and a 52-week high of $8.59.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Monday, November 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.03. Aralez Pharmaceuticals had a negative net margin of 211.76% and a negative return on equity of 65.67%. The firm earned $136 million during the quarter, compared to the consensus estimate of $12.23 million. During the same quarter in the prior year, the business earned ($0.25) EPS. Aralez Pharmaceuticals’s revenue was up 134.5% on a year-over-year basis. Equities research analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.47) earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in ARLZ. Ancora Advisors LLC raised its position in Aralez Pharmaceuticals by 1,384.0% in the second quarter. Ancora Advisors LLC now owns 246,683 shares of the company’s stock valued at $814,000 after buying an additional 230,060 shares during the last quarter. Isthmus Partners LLC raised its position in Aralez Pharmaceuticals by 130.8% in the second quarter. Isthmus Partners LLC now owns 109,495 shares of the company’s stock valued at $361,000 after buying an additional 62,053 shares during the last quarter. Clear Harbor Asset Management LLC bought a new position in Aralez Pharmaceuticals during the second quarter valued at $261,000. GSA Capital Partners LLP raised its position in Aralez Pharmaceuticals by 55.8% in the second quarter. GSA Capital Partners LLP now owns 92,395 shares of the company’s stock valued at $305,000 after buying an additional 33,100 shares during the last quarter. Finally, Drill Craig A raised its position in Aralez Pharmaceuticals by 72.3% in the second quarter. Drill Craig A now owns 584,600 shares of the company’s stock valued at $1,929,000 after buying an additional 245,300 shares during the last quarter. 50.40% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts recently weighed in on the company. Chardan Capital restated a “buy” rating and set a $10.00 price objective on shares of Aralez Pharmaceuticals in a research report on Sunday, August 14th. Guggenheim restated a “buy” rating and set a $12.00 price objective on shares of Aralez Pharmaceuticals in a research report on Monday, August 15th. Finally, Bloom Burton reiterated an “accumulate” rating on shares of Aralez Pharmaceuticals in a research report on Tuesday, November 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $10.33.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Stock Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.